Vir Biotechnology has been granted a patent for a monoclonal antibody that targets the Staphylococcus aureus ClfA protein, potentially offering a new treatment for S. aureus infections. The patent also covers bispecific antibodies that target both ClfA and the S. aureus alpha toxin protein. GlobalData’s report on Vir Biotechnology gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Vir Biotechnology, Peptide pharmacophores was a key innovation area identified from patents. Vir Biotechnology's grant share as of May 2024 was 18%. Grant share is based on the ratio of number of grants to total number of patents.
Monoclonal antibody for treating staphylococcus aureus infection
A recently granted patent (Publication Number: US11970527B2) discloses a composition comprising specific antibodies or antigen-binding fragments that target Staphylococcus aureus (S. aureus) ClfA protein and alpha toxin (AT) protein. The antibodies in the composition are designed with precise amino acid sequences for the variable heavy chain (VH), variable light chain (VL), and heavy chain constant domain to ensure effective binding to the targeted proteins. Additionally, the composition includes IgG1 antibodies that specifically bind to either the S. aureus ClfA protein or AT protein, with variations in heavy chain constant domains and mutations like YTE mutation for enhanced efficacy.
Furthermore, the patent details various embodiments of the composition, specifying different amino acid sequences for the heavy and light chains of the antibodies targeting S. aureus ClfA protein and AT protein. These embodiments include variations in heavy chain constant domains, mutations, and the use of IgG1 antibodies for specific binding. The composition's design allows for a tailored approach to combatting S. aureus infections by precisely targeting key proteins involved in the pathogenicity of the bacterium. The patent highlights the importance of these specific antibody compositions in potentially improving treatment outcomes for S. aureus infections, offering a novel and targeted therapeutic option in the fight against antibiotic-resistant strains of the bacterium.
To know more about GlobalData’s detailed insights on Vir Biotechnology, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
